BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novozymes Biopharma Presents Research on Recombinant Human Albumin at 2011 PepTalk Conference


1/6/2011 11:15:09 AM

Nottingham, UK (January 6 2011) Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, is presenting two scientific posters on the manufacturing and use of recombinant albumin in formulation during PepTalk 2011, 10-14 January, San Diego, US. The posters cover the company's latest research in the use of recombinant human albumin and its ability to address many of the formulation challenges faced by the industry. For more information or to request a copy of the scientific posters, please visit booth #14 at PepTalk 2011 or www.biopharma.novozymes.com

The first poster entitled "Recombinant human albumin: A multifunctional excipient for stable therapeutic protein formulations" demonstrates the unmatched ability of recombinant albumin to protect therapeutic proteins against chemical and physical degradation. The second, entitled "Optimizing Saccharomyces cerevisiae for the rapid development of animal-free biopharmaceutical manufacturing processes", provides insight into the benefits of the yeast strain in the production of recombinant proteins.

The two posters offer protein scientists new insight into formulation and manufacturing and highlight how recombinant albumin can help optimize current processes. The latest innovative solutions are described, which help to overcome some of the main challenges associated with the manufacture of protein therapeutics and biologics formulation development.

"Novozymes is delighted to present this information on the company's latest developments in recombinant albumin", said Dermot Pearson, marketing director at Novozymes Biopharma. "As one of the industry leaders, we believe that our studies significantly contribute to the development of the field and welcome the opportunity to share our advances with industry experts who can also benefit from the leading edge data."

For further information on Novozymes products or to request a copy of the scientific posters, please visit www.biopharma.novozymes.com.

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.

Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Contacts:

Novozymes Biopharma: Sally Vernon, Customer Communications Manager SYKE@novozymes.com Tel. +44 115 955 3355

Corporate Contacts:

Press and media: Johan Melchior Tel. (direct): +45 4446 0690 Tel. (mobile): +45 3077 0690 René Tronborg Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274 Paige Donnelly (USA) Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501

Investor relations:

Tobias Bjørklund (USA) Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES